HALO logo

Halozyme Therapeutics, Inc. (HALO) Return On Equity

Annual ROE:

198.42%-23.65%(-10.65%)
December 31, 2024

Summary

  • As of today, HALO annual return on equity is 198.42%, with the most recent change of -23.65% (-10.65%) on December 31, 2024.
  • During the last 3 years, HALO annual ROE has fallen by -33.02% (-14.27%).
  • HALO annual ROE is now -14.27% below its all-time high of 231.44%, reached on December 31, 2021.

Performance

1-Year Change

-10.65%

3-Year Change

-14.27%

5-Year Change

+567.86%

15-Year Change

+177.12%

HALO ROE Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

96.75%
HALO annual return on equity is higher than 96.75% of companies in Healthcare sector

Range

All-Time High

231.44%
HALO annual return on equity is currently -14.27% below its historical high of 231.44%

3-Year Low

110.23%
HALO annual return on equity is currently +80.01% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
HALO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
HALO next annual earnings announcement has not yet been scheduled

OtherHALOprofitability metrics

Annual Revenue

$1.02B
HALO annual revenue is $1.02 billion

Annual Net Income

$444.09M
HALO annual net profit is $444.09 million

Annual EPS

$3.43
HALO annual earnings per share is $3.43

Annual ROA

22.79%
HALO annual return on assets is 22.79%

Quarterly ROE:

145.05%+7.63%(+5.55%)
June 30, 2025

Summary

  • As of today, HALO quarterly return on equity is 145.05%, with the most recent change of +7.63% (+5.55%) on June 30, 2025.
  • Over the past year, HALO quarterly ROE has dropped by -32.24% (-18.18%).
  • HALO quarterly ROE is now -86.46% below its all-time high of 1071.19%, reached on June 30, 2017.

Performance

3-Month Change

+5.55%

1-Year Change

-18.18%

3-Year Change

-8.74%

5-Year Change

+655.96%

HALO Quarterly ROE Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

93.77%
HALO quarterly return on equity is higher than 93.77% of companies in Healthcare sector

Range

All-Time High

1071.19%
HALO quarterly return on equity is currently -86.46% below its historical high of 1071.19%

3-Year Low

93.53%
HALO quarterly return on equity is currently +55.08% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2025
HALO previous earnings announcement was published on Jun 30, 2025

Next Quarterly Earnings Report Date

Oct 28, 2025
HALO next earnings announcement is scheduled for Oct 28, 2025

OtherHALOprofitability metrics

Quarterly Revenue

$325.72M
HALO quarterly revenue is $325.72 million

Quarterly Net Income

$165.16M
HALO quarterly net profit is $165.16 million

Quarterly EPS

$1.33
HALO quarterly earnings per share is $1.33

Quarterly ROA

26.53%
HALO quarterly return on assets is 26.53%

ROE Formula

ROE =  Net Income
Shareholders Equity ✕ 100%

Annual ROE

198.42%
HALO annual return on equity is 198.42%

Annual Net Income

$444.09M
HALO annual net profit is $444.09 million

Annual Shareholders Equity

$363.82M
HALO annual stockholders equity is $363.82 million

HALO ROE Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year-10.7%-18.2%
3Y3 Years-14.3%-8.7%
5Y5 Years+567.9%+656.0%

HALO ROE Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Year-14.3%+80.0%-33.8%+55.1%
5Y5-Year-14.3%+567.9%-49.0%+708.5%
All-TimeAll-Time-14.3%+110.1%-86.5%+109.1%

HALO ROE History

DateAnnualQuarterly
Jun 2025
-
145.05%(+5.6%)
Mar 2025
-
137.42%(-15.4%)
Dec 2024
198.42%(-10.6%)
162.37%(+3.7%)
Sep 2024
-
156.62%(-11.7%)
Jun 2024
-
177.29%(-19.1%)
Mar 2024
-
219.05%(+12.0%)
Dec 2023
222.07%(+101.5%)
195.64%(+12.9%)
Sep 2023
-
173.23%(+15.2%)
Jun 2023
-
150.42%(+46.8%)
Mar 2023
-
102.50%(+3.2%)
Dec 2022
110.23%(-52.4%)
99.36%(+6.2%)
Sep 2022
-
93.53%(-41.2%)
Jun 2022
-
158.95%(-32.3%)
Mar 2022
-
234.78%(-4.7%)
Dec 2021
231.44%(+117.7%)
246.45%(-13.4%)
Sep 2021
-
284.47%(+35.1%)
Jun 2021
-
210.63%(+24.3%)
Mar 2021
-
169.44%(+32.7%)
Dec 2020
106.33%(+350.7%)
127.70%(+611.8%)
Sep 2020
-
17.94%(+168.8%)
Jun 2020
-
-26.09%(+40.4%)
Mar 2020
-
-43.78%(-34.0%)
Dec 2019
-42.41%(-20.7%)
-32.66%(-104.9%)
Sep 2019
-
-15.94%(+5.9%)
Jun 2019
-
-16.94%(+15.8%)
Mar 2019
-
-20.13%(+39.0%)
Dec 2018
-35.14%(-149.1%)
-33.00%(-250.3%)
Sep 2018
-
21.95%(-50.6%)
Jun 2018
-
44.40%(-29.2%)
Mar 2018
-
62.70%(-50.6%)
Dec 2017
71.60%(+103.7%)
126.99%(+107.9%)
Sep 2017
-
-1600.63%(-249.4%)
Jun 2017
-
1071.19%(+114.6%)
Mar 2017
-
499.09%(+136.7%)
Dec 2016
-1958.98%(-2463.4%)
-1358.50%(-289.3%)
Sep 2016
-
-348.93%(-71.7%)
Jun 2016
-
-203.24%(-111.3%)
Mar 2016
-
-96.17%(-21.7%)
Dec 2015
-76.42%(+88.1%)
-79.03%(+24.1%)
Sep 2015
-
-104.11%(-24.1%)
Jun 2015
-
-83.89%(+29.0%)
Mar 2015
-
-118.18%(+36.6%)
Dec 2014
-640.18%(-10.7%)
-186.46%(+39.3%)
Sep 2014
-
-307.15%(+19.9%)
Jun 2014
-
-383.27%(+27.3%)
Mar 2014
-
-526.96%(+13.9%)
Dec 2013
-578.45%
-612.00%(-158.9%)
DateAnnualQuarterly
Sep 2013
-
-236.39%(-50.5%)
Jun 2013
-
-157.03%(-53.4%)
Mar 2013
-
-102.34%(+0.2%)
Dec 2012
-179.24%(-41.7%)
-102.50%(+27.3%)
Sep 2012
-
-141.08%(-38.7%)
Jun 2012
-
-101.75%(-23.0%)
Mar 2012
-
-82.75%(+23.1%)
Dec 2011
-126.52%(+67.6%)
-107.59%(-36.8%)
Sep 2011
-
-78.67%(+67.1%)
Jun 2011
-
-239.44%(+51.7%)
Mar 2011
-
-495.43%(+16.3%)
Dec 2010
-390.69%(+25.4%)
-592.24%(+0.4%)
Sep 2010
-
-594.84%(+23.2%)
Jun 2010
-
-774.05%(-41.5%)
Mar 2010
-
-546.89%(-29.8%)
Dec 2009
-523.80%(-293.7%)
-421.42%(-25.7%)
Sep 2009
-
-335.33%(-31.1%)
Jun 2009
-
-255.78%(-33.2%)
Mar 2009
-
-192.02%(-52.3%)
Dec 2008
-133.03%(-125.1%)
-126.07%(-50.8%)
Sep 2008
-
-83.58%(-28.6%)
Jun 2008
-
-64.98%(-20.9%)
Mar 2008
-
-53.76%(-15.8%)
Dec 2007
-59.11%(+17.3%)
-46.41%(-1.9%)
Sep 2007
-
-45.56%(+7.6%)
Jun 2007
-
-49.29%(+26.0%)
Mar 2007
-
-66.61%(+21.4%)
Dec 2006
-71.46%(+11.1%)
-84.75%(+15.1%)
Sep 2006
-
-99.87%(+8.7%)
Jun 2006
-
-109.40%(+1.3%)
Mar 2006
-
-110.83%(+0.2%)
Dec 2005
-80.38%(+34.4%)
-111.04%(+21.3%)
Sep 2005
-
-141.14%(-2.2%)
Jun 2005
-
-138.08%(-1.5%)
Mar 2005
-
-136.00%(+14.7%)
Dec 2004
-122.57%(+24.9%)
-159.48%(+34.2%)
Sep 2004
-
-242.55%(-70.4%)
Jun 2004
-
-142.37%(-51.2%)
Mar 2004
-
-94.16%(+25.2%)
Dec 2003
-163.26%(-37.0%)
-125.93%(-55.3%)
Sep 2003
-
-81.10%(-13.7%)
Jun 2003
-
-71.35%(+20.0%)
Mar 2003
-
-89.23%(-35.5%)
Dec 2002
-119.16%(+31.6%)
-65.86%(-251.6%)
Sep 2002
-
-18.73%(-147.4%)
Jun 2002
-
-7.57%(-126.4%)
Mar 2002
-
28.66%
Dec 2001
-174.12%
-

FAQ

  • What is Halozyme Therapeutics, Inc. annual return on equity?
  • What is the all-time high annual ROE for Halozyme Therapeutics, Inc.?
  • What is Halozyme Therapeutics, Inc. annual ROE year-on-year change?
  • What is Halozyme Therapeutics, Inc. quarterly return on equity?
  • What is the all-time high quarterly ROE for Halozyme Therapeutics, Inc.?
  • What is Halozyme Therapeutics, Inc. quarterly ROE year-on-year change?

What is Halozyme Therapeutics, Inc. annual return on equity?

The current annual ROE of HALO is 198.42%

What is the all-time high annual ROE for Halozyme Therapeutics, Inc.?

Halozyme Therapeutics, Inc. all-time high annual return on equity is 231.44%

What is Halozyme Therapeutics, Inc. annual ROE year-on-year change?

Over the past year, HALO annual return on equity has changed by -23.65% (-10.65%)

What is Halozyme Therapeutics, Inc. quarterly return on equity?

The current quarterly ROE of HALO is 145.05%

What is the all-time high quarterly ROE for Halozyme Therapeutics, Inc.?

Halozyme Therapeutics, Inc. all-time high quarterly return on equity is 1071.19%

What is Halozyme Therapeutics, Inc. quarterly ROE year-on-year change?

Over the past year, HALO quarterly return on equity has changed by -32.24% (-18.18%)
On this page